

Luis Bahamondes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5916119/publications.pdf>

Version: 2024-02-01

222
papers

4,992
citations

87888

38
h-index

144013

57
g-index

308
all docs

308
docs citations

308
times ranked

3126
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. <i>Human Reproduction</i> , 2005, 20, 1993-1998.	0.9	312
2	Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. <i>Contraception</i> , 2002, 65, 129-132.	1.5	215
3	Depression in women with endometriosis with and without chronic pelvic pain. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006, 85, 88-92.	2.8	146
4	Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. <i>Contraception</i> , 2007, 76, 195-199.	1.5	124
5	Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. <i>Human Reproduction Update</i> , 2015, 21, 640-651.	10.8	121
6	The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. <i>Contraception</i> , 2000, 62, 23-27.	1.5	86
7	Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. <i>Contraception</i> , 2007, 75, S134-S139.	1.5	86
8	The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. <i>Contraception</i> , 2011, 83, 202-210.	1.5	84
9	A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. <i>Human Reproduction</i> , 2015, 30, 2527-2538.	0.9	76
10	Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. <i>Contraception</i> , 2011, 84, e11-e16.	1.5	74
11	Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. <i>Human Reproduction</i> , 2016, 31, 2491-2498.	0.9	73
12	Contraception and reproductive planning during the COVID-19 pandemic. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 615-622.	3.1	73
13	A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. <i>Human Reproduction</i> , 2014, 29, 1393-1399.	0.9	67
14	The Practice of Hatha Yoga for the Treatment of Pain Associated with Endometriosis. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 45-52.	2.1	66
15	A prospective study of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. <i>Human Reproduction</i> , 2006, 21, 466-470.	0.9	61
16	Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. <i>Fertility and Sterility</i> , 2008, 90, 965-971.	1.0	59
17	Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 378-385.	2.1	59
18	Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. <i>Fertility and Sterility</i> , 2018, 110, 1129-1136.	1.0	58

#	ARTICLE	IF	CITATIONS
19	Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. <i>Contraception</i> , 2009, 80, 84-89.	1.5	57
20	Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study. <i>Contraception</i> , 2002, 65, 325-328.	1.5	56
21	Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17 β -Estradiol. <i>Obstetrics and Gynecology</i> , 2012, 119, 989-999.	2.4	55
22	Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. <i>Contraception</i> , 2010, 81, 107-111.	1.5	54
23	Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. <i>Contraception</i> , 2001, 64, 223-225.	1.5	49
24	TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. <i>Contraception</i> , 2005, 72, 337-341.	1.5	49
25	Long-acting reversible contraceptive (LARCs) methods. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 66, 28-40.	2.8	48
26	Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus. <i>Fertility and Sterility</i> , 1998, 69, 252-257.	1.0	47
27	Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. <i>The Lancet Global Health</i> , 2019, 7, e1054-e1064.	6.3	47
28	Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 970-982.	2.8	47
29	Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. <i>Human Reproduction</i> , 2010, 25, 1158-1164.	0.9	46
30	Ovarian cysts in users of Implanon [®] and Jadelle [®] subdermal contraceptive implants. <i>Contraception</i> , 2006, 73, 532-536.	1.5	44
31	In vivo assessment of the human sperm acrosome reaction and the expression of glycodeilin-A in human endometrium after levonorgestrel-emergency contraceptive pill administration. <i>Human Reproduction</i> , 2007, 22, 2190-2195.	0.9	43
32	Factors associated with reproductive options in HIV-infected women. <i>Contraception</i> , 2005, 71, 45-50.	1.5	42
33	A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. <i>Human Reproduction</i> , 2006, 21, 1316-1319.	0.9	42
34	The use of vaginal ultrasound to identify copper T IUDs at high risk of expulsion. <i>Contraception</i> , 1996, 54, 287-289.	1.5	40
35	Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. <i>Fertility and Sterility</i> , 2001, 76, 469-473.	1.0	40
36	Self-administration with Uniject [®] of the once-a-month injectable contraceptive Cyclofem [®] . <i>Contraception</i> , 1997, 56, 301-304.	1.5	39

#	ARTICLE	IF	CITATIONS
37	Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena®) in Campinas, Brazil. <i>Contraception</i> , 2000, 62, 59-61.	1.5	39
38	Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. <i>Contraception</i> , 2003, 68, 105-109.	1.5	39
39	Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1387-1391.	1.7	38
40	Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem®. <i>Contraception</i> , 1997, 55, 307-310.	1.5	37
41	Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling – results of an international survey in 10 countries. <i>Contraception</i> , 2012, 86, 631-638.	1.5	36
42	Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. <i>Journal of reproductive medicine, The</i> , 2004, 49, 115-20.	0.2	36
43	Performance of the copper T 200 in parous adolescents: Are copper IUDs suitable for these women?. <i>Contraception</i> , 1993, 48, 23-28.	1.5	35
44	New and emerging contraceptives: a state-of-the-art review. <i>International Journal of Women's Health</i> , 2014, 6, 221.	2.6	35
45	Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2003, 82, 580-2.	2.8	35
46	Infertility care and the introduction of new reproductive technologies in poor resource settings. <i>Reproductive Biology and Endocrinology</i> , 2014, 12, 87.	3.3	32
47	Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives. <i>Journal of Family Planning and Reproductive Health Care</i> , 2014, 40, 54-60.	0.8	32
48	Length of the endometrial cavity as measured by uterine sounding and ultrasonography in women of different parities. <i>Contraception</i> , 2010, 81, 515-519.	1.5	31
49	Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. <i>Contraception</i> , 2014, 90, 117-122.	1.5	31
50	Performance of copper intrauterine devices when inserted after an expulsion. <i>Human Reproduction</i> , 1995, 10, 2917-2918.	0.9	30
51	Body weight and composition in users of levonorgestrel-releasing intrauterine system. <i>Contraception</i> , 2012, 86, 350-353.	1.5	29
52	Management of missing strings in users of intrauterine contraceptives. <i>Contraception</i> , 2012, 86, 354-358.	1.5	29
53	The burden of unintended pregnancies in Brazil: a social and public health system cost analysis. <i>International Journal of Women's Health</i> , 2014, 6, 663.	2.6	29
54	No relationship between the IUD position evaluated by ultrasound and complaints of bleeding and pain. <i>Contraception</i> , 1997, 56, 43-47.	1.5	28

#	ARTICLE	IF	CITATIONS
55	Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function—Depo-Provera, Upjohn Co., Kalamazoo, Michigan.. <i>Fertility and Sterility</i> , 1998, 70, 817-820.	1.0	28
56	The in vitro effect of levonorgestrel on the acrosome reaction of human spermatozoa from fertile men. <i>Contraception</i> , 2003, 68, 55-59.	1.5	28
57	Pain threshold and sleep quality in women with endometriosis. <i>European Journal of Pain</i> , 2015, 19, 15-20.	2.8	27
58	Two-year performance of a Nestorone®-releasing contraceptive implant: a three-center study of 300 women. <i>Contraception</i> , 2004, 69, 137-144.	1.5	26
59	Cytological evaluation and investigation of the vaginal flora of long-term users of the levonorgestrel-releasing intrauterine system (LNG-IUS). <i>Contraception</i> , 2008, 77, 30-33.	1.5	26
60	Inequitable access to assisted reproductive technology for the low-income Brazilian population: a qualitative study. <i>Human Reproduction</i> , 2011, 26, 2054-2060.	0.9	26
61	Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth. <i>Fertility and Sterility</i> , 2013, 100, 445-450.	1.0	26
62	Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic. <i>Human Reproduction</i> , 2014, 29, 2163-2170.	0.9	26
63	Pregnancy outcomes associated with extended use of the 52-mg 20 µg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil. <i>Contraception</i> , 2018, 97, 205-209.	1.5	26
64	A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement. <i>Contraception</i> , 2018, 98, 181-187.	1.5	26
65	Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling. <i>Global Health, Science and Practice</i> , 2017, 5, 534-539.	1.7	25
66	A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel- and levonorgestrel-releasing contraceptive implants. <i>Reproductive Health</i> , 2007, 4, 11.	3.1	24
67	Prostate-specific antigen in vaginal fluid after exposure to known amounts of semen and after condom use: comparison of self-collected and nurse-collected samples. <i>Human Reproduction</i> , 2008, 23, 2444-2451.	0.9	24
68	Pain at insertion of the levonorgestrel-releasing intrauterine system in nulligravida and parous women with and without cesarean section. <i>Contraception</i> , 2013, 88, 164-168.	1.5	24
69	Body weight and body composition of depot medroxyprogesterone acetate users. <i>Contraception</i> , 2014, 90, 182-187.	1.5	24
70	Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. <i>European Journal of Contraception and Reproductive Health Care</i> , 2015, 20, 57-63.	1.5	24
71	Effect of vaginal administration of misoprostol before intrauterine contraceptive insertion following previous insertion failure: a double blind RCT. <i>Human Reproduction</i> , 2015, 30, 1861-1866.	0.9	24
72	Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. <i>Contraception</i> , 2014, 89, 17-21.	1.5	23

#	ARTICLE	IF	CITATIONS
73	Weight variation in a cohort of women using copper IUD for contraception. <i>Contraception</i> , 2003, 68, 27-30.	1.5	22
74	Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. <i>Contraception</i> , 2005, 72, 187-191.	1.5	22
75	Length of the endometrial cavity and intrauterine contraceptive device expulsion. <i>International Journal of Gynecology and Obstetrics</i> , 2011, 113, 50-53.	2.3	22
76	Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate. <i>Journal of Women's Health</i> , 2015, 24, 636-640.	3.3	22
77	Recent advances in managing and understanding menstrual disorders. <i>F1000prime Reports</i> , 2015, 7, 33.	5.9	22
78	Contraceptive sales in the setting of the Zika virus epidemic. <i>Human Reproduction</i> , 2017, 32, 88-93.	0.9	21
79	The in vitro effect of emergency contraception doses of levonorgestrel on the acrosome reaction of human spermatozoa. <i>Contraception</i> , 2005, 72, 225-228.	1.5	20
80	Prevalence of endometrial cancer and hyperplasia in non-symptomatic overweight and obese women. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 207-213.	1.0	20
81	Low priority level for infertility services within the public health sector: a Brazilian case study. <i>Human Reproduction</i> , 2010, 25, 430-435.	0.9	20
82	A Qualitative Study on the Practice of Yoga for Women with Pain-Associated Endometriosis. <i>Journal of Alternative and Complementary Medicine</i> , 2016, 22, 977-982.	2.1	20
83	A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. <i>Human Reproduction</i> , 2016, 31, 530-540.	0.9	20
84	Period poverty: menstrual health hygiene issues among adolescent and young Venezuelan migrant women at the northwestern border of Brazil. <i>Reproductive Health</i> , 2021, 18, 238.	3.1	20
85	Levonorgestrel-releasing intrauterine system (Mirena®) as a therapy for endometrial hyperplasia and carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2003, 82, 580-582.	2.8	19
86	Premenstrual syndrome as reported by Brazilian women. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 40-43.	2.3	19
87	Sexual dysfunction risk and quality of life among women with a history of sexual abuse. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 134, 260-263.	2.3	19
88	Zika virus exposure in pregnancy and its association with newborn visual anomalies and hearing loss. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 277-281.	2.3	19
89	Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. <i>Revista Da Associação Médica Brasileira</i> , 2011, 57, 415-420.	0.7	18
90	Prevalence of fibromyalgia and quality of life in women with and without endometriosis. <i>Gynecological Endocrinology</i> , 2014, 30, 307-310.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Sperm chemorepulsion, a supplementary mechanism to regulate fertilization. <i>Human Reproduction</i> , 2017, 32, 1560-1573.	0.9	18
92	A case series on the use of levonorgestrel 52µg intrauterine system after organ transplant. <i>Contraception</i> , 2018, 98, 252-254.	1.5	18
93	Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020, 25, 133-140.	1.5	18
94	Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. <i>Contraception</i> , 2011, 84, 122-127.	1.5	17
95	Effect of exposure to ulipristal acetate on sperm function. <i>European Journal of Contraception and Reproductive Health Care</i> , 2012, 17, 428-437.	1.5	17
96	Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: An updated review. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2019, 98, 1500-1513.	2.8	17
97	Galactorrhea, Infertility, and Short Luteal Phases in Hyperprolactinemic Women: Early Stage of Amenorrhea-Galactorrhea?. <i>Fertility and Sterility</i> , 1979, 32, 476-477.	1.0	16
98	Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. <i>Contraception</i> , 2006, 73, 97-101.	1.5	16
99	Efficacy and tolerance of metronidazole and miconazole nitrate in treatment of vaginitis. <i>International Journal of Gynecology and Obstetrics</i> , 2008, 102, 287-292.	2.3	16
100	Menstrual bleeding: perspective of Brazilian women. <i>Contraception</i> , 2011, 84, 622-627.	1.5	16
101	Family planning: an essential health activity in the pandemic of SARS-CoV-2. <i>European Journal of Contraception and Reproductive Health Care</i> , 2020, 25, 319-320.	1.5	16
102	Levonorgestrel-releasing intrauterine system: uses and controversies. <i>Expert Review of Medical Devices</i> , 2008, 5, 437-445.	2.8	15
103	Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 318-322.	1.5	15
104	Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1732-1737.	1.3	15
105	Reproductive health among Venezuelan migrant women at the north western border of Brazil: A qualitative study. <i>Journal of Migration and Health</i> , 2021, 4, 100060.	3.0	15
106	Opinion and experience of Brazilian women regarding menstrual bleeding and use of combined oral contraceptives. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 117, 5-9.	2.3	14
107	In vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes. <i>Reproductive Biology and Endocrinology</i> , 2012, 10, 8.	3.3	14
108	Knowledge and attitudes of Latin American obstetricians and gynecologists regarding intrauterine contraceptives. <i>International Journal of Women's Health</i> , 2015, 7, 717.	2.6	14

#	ARTICLE	IF	CITATIONS
109	Endometrial chemokines, uterine natural killer cells and mast cells in long-term users of the levonorgestrel-releasing intrauterine system. <i>Human Reproduction</i> , 2006, 21, 1129-1134.	0.9	13
110	Usefulness of FSH measurements for determining menopause in long-term users of depot medroxyprogesterone acetate over 40 years of age. <i>Contraception</i> , 2007, 76, 282-286.	1.5	13
111	The use of long-acting reversible contraceptives in Latin America and the Caribbean: current landscape and recommendations. <i>Human Reproduction Open</i> , 2018, 2018, hox030.	5.4	13
112	T-shaped IUD move vertically with endometrial growth and involution during the menstrual cycle. <i>Contraception</i> , 1998, 57, 413-415.	1.5	12
113	<i>In vitro</i> and <i>in vivo</i> effects of ulipristal acetate on fertilization and early embryo development in mice. <i>Human Reproduction</i> , 2016, 31, 53-59.	0.9	12
114	Current practice in the management of symptoms of endometriosis: a survey of Brazilian gynecologists. <i>Revista Da Associação Médica Brasileira</i> , 2007, 53, 525-529.	0.7	12
115	Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. <i>Journal of reproductive medicine, The</i> , 2003, 48, 637-40.	0.2	12
116	Sustained Hyperprolactinemia in a Normally Menstruating Woman with Apparently Normal Ovarian Function. <i>Fertility and Sterility</i> , 1980, 34, 282-284.	1.0	11
117	Carbohydrate complexity and proportion of serum FSH isoforms reflect pituitary-ovarian activity in perimenopausal women and depot medroxyprogesterone acetate users. <i>Clinical Endocrinology</i> , 2009, 71, 558-565.	2.4	11
118	Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. <i>Contraception</i> , 2012, 86, 244-250.	1.5	11
119	Comparison of two cohorts of women who expelled either a copper intrauterine device or a levonorgestrel-releasing intrauterine system. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 554-559.	1.3	11
120	Sexual Function and Quality of Life in a Cohort of Brazilian Users of Two Kind of Intrauterine Contraceptives. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2019, 41, 236-241.	0.8	11
121	Postplacental placement of intrauterine devices: A randomized clinical trial. <i>Contraception</i> , 2020, 101, 153-158.	1.5	11
122	Evaluation of clinical performance when intrauterine devices are inserted by different categories of healthcare professional. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 196-201.	2.3	11
123	Intrauterine device use is safe among nulligravidas and adolescent girls. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 641-648.	2.8	11
124	Comparison of local signs and symptoms after the insertion of NORPLANT® implants with and without a scalpel. <i>Contraception</i> , 1991, 44, 217-221.	1.5	10
125	Correlation between endometrial histology, microvascular density and calibre, matrix metalloproteinase-3 and bleeding pattern in women using a levonorgestrel-releasing intrauterine system. <i>Human Reproduction</i> , 2004, 19, 1778-1784.	0.9	10
126	In vitro effect of levonorgestrel on sperm fertilizing capacity and mouse embryo development. <i>Contraception</i> , 2005, 72, 71-76.	1.5	10

#	ARTICLE	IF	CITATIONS
127	Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials. <i>Contraception</i> , 2019, 100, 438-444.	1.5	10
128	One-year follow up on post-placental IUD insertion: A randomized clinical trial. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 596-603.	2.8	10
129	Narratives of experiences of violence of Venezuelan migrant women sheltered at the northwestern Brazilian border. <i>PLoS ONE</i> , 2021, 16, e0260300.	2.5	10
130	Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate. <i>Contraception</i> , 2008, 78, 365-369.	1.5	9
131	A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. <i>Contraception</i> , 2011, 84, e31-e37.	1.5	9
132	Effects of ulipristal acetate on sperm DNA fragmentation during <i>in vitro</i> incubation. <i>European Journal of Contraception and Reproductive Health Care</i> , 2013, 18, 355-363.	1.5	9
133	Advances in contraceptive vaginal rings: what does the future hold?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1685-1691.	1.8	9
134	Contraceptive effectiveness, pharmacokinetics, and safety of Sayana® Press when injected every four months: a multicenter phase 3 trial. <i>EClinicalMedicine</i> , 2022, 44, 101273.	7.1	9
135	Use of hormonal contraceptives to control menstrual bleeding: attitudes and practice of Brazilian gynecologists. <i>International Journal of Women's Health</i> , 2013, 5, 795.	2.6	8
136	Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52µg LNG-IUS: a non-inferiority randomised clinical trial. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 344-350.	1.5	8
137	Use of intravaginal electrical stimulation for the treatment of chronic pelvic pain: a randomized, double-blind, crossover clinical trial. <i>Journal of reproductive medicine, The</i> , 2010, 55, 19-24.	0.2	8
138	Brazilian network of COVID-19 during pregnancy (REBRACO: a multicentre study protocol). <i>BMJ Open</i> , 2021, 11, e051284.	1.9	8
139	Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 22-29.	1.5	7
140	Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes. <i>Contraception</i> , 2017, 95, 586-591.	1.5	7
141	Changes in calcium metabolism and bone mineral density in new users of medroxyprogesterone acetate during the first year of use. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 147, 319-325.	2.3	7
142	Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 102-108.	1.5	7
143	Intracervical block for levonorgestrel-releasing intrauterine system placement among nulligravid women: a randomized double-blind controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 245.e1-245.e10.	1.3	7
144	Lack of Influence of Thyroid Hormone on Bone Mineral Density and Body Composition in Healthy Euthyroid Women. <i>Frontiers in Endocrinology</i> , 2019, 10, 890.	3.5	7

#	ARTICLE	IF	CITATIONS
145	Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 240-246.	2.3	7
146	A neglected population: Sexual and reproductive issues among adolescent and young Venezuelan migrant women at the northwestern border of Brazil. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 157, 51-58.	2.3	7
147	Intravaginal electrical stimulation for the treatment of chronic pelvic pain. <i>Journal of reproductive medicine, The</i> , 2005, 50, 267-72.	0.2	7
148	Menstrual pattern and ovarian function in women with hyperprolactinemia. <i>International Journal of Gynecology and Obstetrics</i> , 1985, 23, 31-36.	2.3	6
149	Evaluation of human sperm membrane integrity using the water test and the hypoosmotic test. <i>Andrologia</i> , 2001, 33, 75-77.	2.1	6
150	Bone mineral density in users of two kinds of once-a-month combined injectable contraceptives. <i>Contraception</i> , 2006, 74, 259-263.	1.5	6
151	Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1054-1060.	1.3	6
152	Modern contraceptives in sub-Saharan African countries. <i>The Lancet Global Health</i> , 2019, 7, e819-e820.	6.3	6
153	A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52µg levonorgestrel intrauterine system. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 10-15.	2.3	6
154	Mechanisms involved in the contraceptive effects of ulipristal acetate. <i>Reproduction</i> , 2020, 159, R139-R149.	2.6	6
155	Assessment of sexual and reproductive access and use of menstrual products among Venezuelan migrant adult women at the Brazilian-Venezuelan border. <i>Journal of Migration and Health</i> , 2022, 5, 100097.	3.0	6
156	Endometrial histology, microvascular density and caliber, and matrix metalloproteinase-3 in users of the Nestorone®-releasing contraceptive implant with and without endometrial breakthrough bleeding. <i>Contraception</i> , 2006, 73, 634-640.	1.5	5
157	Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. <i>European Journal of Contraception and Reproductive Health Care</i> , 2014, 19, 244-249.	1.5	5
158	Knowledge and attitudes of Latin American gynecologists regarding unplanned pregnancy and use of combined oral contraceptives. <i>International Journal of Women's Health</i> , 2015, 7, 485.	2.6	5
159	Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 1331-1336.	1.7	5
160	Barriers to Implementing and Consolidating a Family Planning Program that would meet Brazilian Needs. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2017, 39, 373-375.	0.8	5
161	Stagnant contraceptive sales after the Zika epidemic in Brazil. <i>European Journal of Contraception and Reproductive Health Care</i> , 2017, 22, 381-383.	1.5	5
162	Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1597-1605.	1.7	5

#	ARTICLE	IF	CITATIONS
163	Strengthening research capacity through regional partners: the HRP Alliance at the World Health Organization. <i>Reproductive Health</i> , 2020, 17, 131.	3.1	5
164	Acceptability of ENGâ€releasing subdermal implants among postpartum Brazilian young women during the COVIDâ€19 pandemic. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 106-112.	2.3	5
165	Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-ProveraÂ®: a randomized trial. <i>Contraception: X</i> , 2021, 3, 100070.	1.8	5
166	Health systems analysis and evaluation of the barriers to availability, utilisation and readiness of sexual and reproductive health services in COVID-19-affected areas: a WHO mixed-methods study protocol. <i>BMJ Open</i> , 2022, 12, e057810.	1.9	5
167	Physician-patient communication in the prevention of female reproductive tract infections: some limitations. <i>Cadernos De Saude Publica</i> , 2000, 16, 249-253.	1.0	4
168	Users?? Perspectives on Bleeding Patterns after Two Years of Levonorgestrel-Releasing Intrauterine System Use. <i>Drugs in R and D</i> , 2002, 3, 387-391.	2.2	4
169	Lipid profile in women over 35 years old using triphasic combined oral contraceptives. <i>Contraception</i> , 2004, 69, 395-399.	1.5	4
170	Perspectives on Premenstrual Syndrome/Premenstrual Dysphoric Disorder. <i>Disease Management and Health Outcomes</i> , 2007, 15, 263-277.	0.4	4
171	Natural Killer Cells and Telomerase in the Endometrium of Patients with Endometriosis. <i>Journal of Endometriosis</i> , 2010, 2, 182-188.	1.0	4
172	Estimated disability-adjusted life years averted by free-of-charge provision of the levonorgestrel-releasing intrauterine system over a 9-year period in Brazil. <i>Journal of Family Planning and Reproductive Health Care</i> , 2017, 43, 181-185.	0.8	4
173	A single post-ovulatory dose of ulipristal acetate impairs post-fertilization events in mice. <i>Molecular Human Reproduction</i> , 2019, 25, 257-264.	2.8	4
174	Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. <i>Contraception: X</i> , 2022, 4, 100073.	1.8	4
175	Implications of cycle length immediately after discontinuation of combined oral contraceptives on use of the Standard Days Method. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 111, 78-81.	2.3	3
176	The Use of Long Acting Reversible Contraceptives and the Relationship between Discontinuation Rates due to Menopause and to Female and Male Sterilizations. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2016, 38, 210-217.	0.8	3
177	Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 285-289.	1.5	3
178	Follow-up visits to check strings after intrauterine contraceptive placement cannot predict or prevent future expulsion. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 97-101.	1.5	3
179	ConsequÃªncias da vasectomia: experiÃªncia de homens que se submeteram Ã cirurgia em Campinas (SÃ£o Tj ETQg1 1 0.784314 rgB	0.3	3
180	Assessment of the availability of sexual and reproductive healthcare for Venezuelan migrant women during the SARS-CoV-2 pandemic at the north-western border of Brazil-Venezuela. <i>Journal of Migration and Health</i> , 2022, 5, 100092.	3.0	3

#	ARTICLE	IF	CITATIONS
181	Assessment of the Use of Two New Low-Dose Levonorgestrel-Releasing Intrauterine Systems as Contraceptives. <i>Women's Health</i> , 2012, 8, 235-238.	1.5	2
182	Understanding and attitudes of Brazilian men with regard to premenstrual syndrome. <i>International Journal of Gynecology and Obstetrics</i> , 2013, 121, 31-34.	2.3	2
183	Considering the risks and benefits of intrauterine devices: should clinician advice now be changed?. <i>Clinical Practice (London, England)</i> , 2013, 10, 19-30.	0.1	2
184	Comment on "Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives": authors' response. <i>Journal of Family Planning and Reproductive Health Care</i> , 2014, 40, 235.2-235.	0.8	2
185	Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding. <i>Obstetrics and Gynecology International</i> , 2016, 2016, 1-6.	1.3	2
186	Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive. <i>Contraception</i> , 2018, 98, 144-150.	1.5	2
187	Safety and bleeding patterns of the levonorgestrel 52µg intrauterine system among women with thrombosis or coagulopathy. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 355-361.	2.3	2
188	The benefits and limitations of donating new contraceptive technology: The case of the International Contraceptive Access (ICA) Foundation and the LNG IUS Program in Brazil. <i>Contraception</i> , 2020, 101, 367-369.	1.5	2
189	Analysis of 16 years of calls and emails to the Options for Sexual Health "Sex Sense" information and referral service. <i>Canadian Journal of Human Sexuality</i> , 2019, 28, 38-45.	1.6	2
190	Relationship between chronic pelvic pain and functional constipation in women of reproductive age. <i>Journal of reproductive medicine, The</i> , 2011, 56, 425-30.	0.2	2
191	Reasons for satisfaction with the use of the 52µg levonorgestrel intrauterine system. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 577-582.	2.3	2
192	Awareness of the non-contraceptive benefits of reversible contraceptive methods in a cohort of Brazilian women: an exploratory study. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, , 1-6.	1.5	2
193	Perspectives of health care providers regarding the levonorgestrel-releasing intrauterine system. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, 27, 208-211.	1.5	2
194	Acceptability of the contraceptive Sayana® Press when injected every four months: Results from a twelve-month trial in Brazil, Chile and the Dominican Republic. <i>Contraception</i> , 2022, 113, 95-100.	1.5	2
195	Does the use of hormonal contraceptives affect bone mineral density?. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 141-153.	0.4	1
196	Use of combined oral contraceptives for the management of heavy menstrual bleeding. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 485-489.	0.4	1
197	Emerging female contraceptives. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 373-387.	2.4	1
198	Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 408-411.	1.5	1

#	ARTICLE	IF	CITATIONS
199	Predictors of severe pain during insertion of the levonorgestrel 52µg intrauterine system among nulligravid women. <i>Contraception</i> , 2020, 102, 267-269.	1.5	1
200	Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report. <i>Gynecological Endocrinology</i> , 2021, , 1-4.	1.7	1
201	Effect of levonorgestrel as emergency contraception on spermatozoa function: a review. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 123-130.	0.4	1
202	Expulsion and continuation rates of the levonorgestrel 52mg intrauterine system was similar among nulligravid and parous users. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	2.3	1
203	Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	2.3	1
204	Natural contraception apps knowledge among Brazilian women and Obstetrics and Gynaecology residents. <i>European Journal of Contraception and Reproductive Health Care</i> , 2022, , 1-5.	1.5	1
205	Knowledge, Attitude, and Practices Related to the SARS-CoV-2 Pandemic among Women Seeking Contraceptive Methods. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 391-397.	0.8	1
206	Contracepção hormonal e anti-retrovirais em mulheres infectadas pelo HIV. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2006, 28, 680.	0.8	0
207	Erratum to "Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate" [<i>Contraception</i> 78 (2008) 365-369]. <i>Contraception</i> , 2009, 79, 159-160.	1.5	0
208	Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2011, 57, 408-413.	0.1	0
209	Re: "Is lipid profile determination necessary in women wishing to use oral contraceptives?" by Machado RB et al.. <i>Contraception</i> , 2013, 87, 864.	1.5	0
210	Comment on "Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives": authors' response. <i>Journal of Family Planning and Reproductive Health Care</i> , 2014, 40, 152-153.	0.8	0
211	Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems. <i>Obstetrics and Gynecology</i> , 2014, 123, 667.	2.4	0
212	Gasto energético e medidas antropométricas de novas usuárias do contraceptivo injetável trimestral de acetato de medroxiprogesterona de depósito. <i>Revista De Nutricao</i> , 2015, 28, 497-504.	0.4	0
213	A Randomized Clinical Trial of the Effect of Intensive Versus Non-intensive Counseling on Discontinuation Rates Due to Bleeding Disturbances of Three Long-Acting Reversible Contraceptives. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 24-26.	0.4	0
214	Body composition in long-term users of depot medroxyprogesterone acetate. <i>Evidence Based Women S Health Journal</i> , 2016, 6, 115-118.	0.0	0
215	Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. <i>Contraception</i> , 2017, 95, 434-435.	1.5	0
216	The Advantages of LARC Methods. <i>Trends in Andrology and Sexual Medicine</i> , 2021, , 101-114.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation. <i>EClinicalMedicine</i> , 2021, 34, 100857.	7.1	0
218	Association between breast cancer risk and levonorgestrel-releasing intrauterine system. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 1750-1750.	2.8	0
219	Effect of ulipristal acetate on gene expression profile in endometrial cells in culture and in vivo upon post-ovulatory administration in fertile women. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, , 1-9.	1.5	0
220	Debate sobre o artigo de Fernando Zegers-Hochschild. <i>Cadernos De Saude Publica</i> , 1998, 14, S21-S22.	1.0	0
221	Female body mass index and the selection of a long-acting reversible contraception for the first time. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	2.3	0
222	Potential of LARC to recover loss in satisfied demand for modern contraception after the COVID-19 pandemic: a case scenario analysis of Brazil and Mexico. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2022, 46, 1.	1.1	0